Writing in The Hill, David Balto, a former policy director of the Federal Trade Commission in the Obama Administration, and Wayne Winegarden, an economist with the Pacific Research Institute, discuss the growing pressure on public officials to address anti-competitive industry practices known as “rebate walls” or “rebate traps”. “Rebates and discounts are generally […]
Tag: drug prices
RealClearHealth: Lower Drug Costs By Demolishing “Rebate Walls”
Writing in RealClearHealth, Dr. Madelaine A. Feldman, a rheumatologist, and Wayne Winegarden, an economist with the Pacific Research Institute, explain how the Biden administration and state attorneys general could lower drug prices by ending anti-competitive industry practices known as “rebate walls“. “Rebate walls, also known as rebate traps, block competition in parts of […]
Prescription Drug “Rebates” Raise Prices, Limit Drug Choice, and Make Patients Sicker
By Erik Sass Anti-competitive practices in the prescription drug marketplace like “rebate walls” routinely cost ordinary Americans thousands of dollars every year while restricting patient access to medications. These costs and restrictions will only grow more onerous in years to come, unless the incoming Biden administration acts swiftly to take on these anti-market arrangements. […]
Have health insurance? Then you shouldn’t pay full price for insulin
The end of January is a special time for many of us — and not always a happy one. It’s a time to realize we’ve failed to keep new year’s resolutions, to remember how much we hate cold weather, and to chafe at the U.S. healthcare system as newly reset insurance deductibles […]
Government Tries to Regulate Drug Prices by Violating the First Amendment
By Ilya Shapiro and Dennis Garcia, courtesy of the Cato Institute Pharmaceutical companies rely on direct-to-consumer advertisements to reach potential customers and extol the benefits of their medications. This type of “commercial speech” enjoys protection under the First Amendment, though not to the same degree as other forms of expression. Merck v. HHS tests the limits […]
Drug reference pricing threatens patient health, innovation
By Erik Sass, TES Editor-in-Chief Some recent proposals to lower drug prices are not just counterproductive but dangerous, according to an international panel of expert economists convened by the Competitive Enterprise Institute at the National Press Club on Tuesday, November 5, 2019. The panelists warned that “foreign reference pricing” — a practice […]